US Stock MarketDetailed Quotes
NAMS NewAmsterdam Pharma
- 21.990
- +0.550+2.57%
Close Apr 26 16:00 ET
- 21.850
- -0.140-0.64%
Post 18:25 ET
1.96BMarket Cap-10227P/E (TTM)
22.120High21.020Low62.74KVolume21.130Open21.440Pre Close1.36MTurnover0.21%Turnover RatioLossP/E (Static)89.27MShares26.35052wk High6.81P/B650.54MFloat Cap5.63352wk Low--Dividend TTM29.58MShs Float32.880Historical High--Div YieldTTM5.13%Amplitude5.633Historical Low21.709Avg Price1Lot Size
NewAmsterdam Pharma Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (FY)Dec 31, 2022 | (FY)Dec 31, 2021 | (FY)Dec 31, 2020 | |
|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||
| Cash flow from continuing operating activities | -1,424.13%-141.22M | 136.14%10.67M | -301.92%-29.51M | -7.34M |
| Net income from continuing operations | -681.73%-176.94M | 45.83%-22.63M | -490.94%-41.79M | ---7.07M |
| Operating gains losses | -51.56%5.23M | 1,410.81%10.79M | -2,688.05%-823K | ---29.52K |
| Depreciation and amortization | 444.44%49K | 80.00%9K | 306.52%5K | --1.23K |
| Other non cash items | -99.93%6K | 8.61%8.01M | 1,717.51%7.38M | --405.88K |
| Change In working capital | -43.45%5.87M | 132.06%10.37M | 788.31%4.47M | ---649.41K |
| -Change in prepaid assets | 196.32%4.03M | 20.01%-4.19M | -213.47%-5.23M | ---1.67M |
| -Change in payables and accrued expense | 372.35%10.54M | -139.89%-3.87M | 851.52%9.7M | --1.02M |
| -Change in other working capital | -147.24%-8.71M | --18.43M | ---- | ---- |
| Cash from discontinued investing activities | ||||
| Operating cash flow | -1,424.13%-141.22M | 136.14%10.67M | -301.92%-29.51M | ---7.34M |
| Investing cash flow | ||||
| Cash flow from continuing investing activities | 89.14%-24K | -820.83%-221K | -50.10%-24K | -15.99K |
| Net PPE purchase and sale | 89.14%-24K | -820.83%-221K | -50.10%-24K | ---15.99K |
| Cash from discontinued investing activities | ||||
| Investing cash flow | 89.14%-24K | -820.83%-221K | -50.10%-24K | ---15.99K |
| Financing cash flow | ||||
| Cash flow from continuing financing activities | -97.73%8.91M | 362.68%391.91M | 508.37%84.7M | 13.92M |
| Net issuance payments of debt | --0 | --747K | --0 | --13.92M |
| Net common stock issuance | --0 | 368.63%396.95M | --84.7M | --0 |
| Proceeds from stock option exercised by employees | --8.91M | --0 | --0 | ---- |
| Net other financing activities | ---- | ---5.79M | ---- | ---- |
| Cash from discontinued financing activities | ||||
| Financing cash flow | -97.73%8.91M | 362.68%391.91M | 508.37%84.7M | --13.92M |
| Net cash flow | ||||
| Beginning cash position | 677.85%467.73M | 523.38%60.13M | 213.70%9.65M | --3.07M |
| Current changes in cash | -132.89%-132.33M | 629.32%402.35M | 740.43%55.17M | --6.56M |
| Effect of exchange rate changes | -3.73%5.05M | 212.06%5.25M | -15,964.44%-4.68M | --29.52K |
| End cash Position | -27.21%340.45M | 677.85%467.73M | 521.92%60.13M | --9.67M |
| Free cash flow | -1,452.37%-141.24M | 135.36%10.44M | -301.37%-29.54M | ---7.36M |
| Currency Unit | USD | USD | USD | USD |
| Audit Opinions | Unqualified Opinion | Unqualified Opinion | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg